5 Best Up and Coming Pharmaceutical Stocks to Buy Now

3. Alto Neuroscience, Inc. (NYSE:ANRO)

Number of Hedge Fund Holders: 30

Alto Neuroscience, Inc. (NYSE:ANRO) is one of the best up and coming stocks on our list.

On June 15, ALTO highlighted the publication in Nature Medicine of Prime-Praxol, an independent randomized, double-blind, placebo-controlled study evaluating pramipexole, a dopamine agonist, in patients with mood disorders and clinically significant anhedonia. The trial, independently conducted and funded by investigators at Lund University in Sweden, included adults with major depressive disorder, dysthymia, or bipolar depression. Participants received flexible-dose pramipexole or placebo alongside existing treatment for nine weeks, followed by a six-month open-label extension. The study showed that pramipexole produced a greater reduction in anhedonia compared with placebo, with improvements sustained during the extension period.

In another company news, it was reported on May 28 that Alto Neuroscience, Inc. (NYSE:ANRO) announced the appointment of Andrew Miller, Ph.D., to its Board of Directors, effective May 27, 2026. The company highlighted Dr. Miller’s extensive experience in neuropsychiatric drug development, strategic leadership, and advancing novel therapies for serious mental health conditions. Miller previously served as Founder and President of R&D at Karuna Therapeutics, where he played a key role in developing KarXT, a schizophrenia treatment later acquired by Bristol Myers Squibb. ALTO noted that its expertise will support the company as it advances ALTO-207 in treatment-resistant depression and progresses its broader precision psychiatry pipeline toward future clinical milestones.

Alto Neuroscience, Inc. (NYSE:ANRO) is a clinical-stage biotech company developing personalized treatments for neuropsychiatric disorders using its AI-driven Precision Psychiatry Platform.